IN8bio Announces Presentations At The Society For Immunology Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio has announced that it will present biological correlative data from the ongoing Phase 1 clinical trial of INB-200, targeting newly diagnosed glioblastoma multiforme (GBM), and pre-clinical insights on its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunology of Cancer 38th Annual Meeting.
September 29, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's announcement of presenting data from its ongoing Phase 1 clinical trial and pre-clinical insights at a major conference could potentially increase investor interest and confidence in the company.
Presentations at major conferences often serve as platforms for companies to showcase their progress and potential. The announcement that IN8bio will be presenting data from its ongoing Phase 1 clinical trial and pre-clinical insights could potentially increase investor interest and confidence in the company, thereby positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100